单位：[1]Shanghai Inst Hematol, Shanghai, Peoples R China[2]Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China[3]Shandong Canc Hosp, Jinan, Peoples R China[4]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China河北医科大学第四医院[5]HUST, Tongji Hosp, Tongji Med Coll, Shanghai, Peoples R China[6]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[7]Henan Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[8]Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China[9]Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Gen,Sch Med, Shanghai, Peoples R China
Xu Peng-Peng,Liu Tingbo,Li Zengjun,et al.Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma: A real-world analysis[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA：
Xu, Peng-Peng,Liu, Tingbo,Li, Zengjun,Li, Zheng,Huang, Wei...&Zhao, Weili.(2022).Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma: A real-world analysis.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Xu, Peng-Peng,et al."Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma: A real-world analysis".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学